These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15886147)

  • 1. Financing vaccines: in search of solutions that work.
    Iglehart JK
    Health Aff (Millwood); 2005; 24(3):594-5. PubMed ID: 15886147
    [No Abstract]   [Full Text] [Related]  

  • 2. Global perspectives on vaccine financing.
    Berman S; Giffin RB
    Expert Rev Vaccines; 2004 Oct; 3(5):557-62. PubMed ID: 15485335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The U.S. vaccine supply.
    Schwartz HK
    N Engl J Med; 2005 Mar; 352(10):1046-7; author reply 1046-7. PubMed ID: 15762001
    [No Abstract]   [Full Text] [Related]  

  • 4. The U.S. vaccine supply.
    Hinman AR
    N Engl J Med; 2005 Mar; 352(10):1046-7; author reply 1046-7. PubMed ID: 15758020
    [No Abstract]   [Full Text] [Related]  

  • 5. Determinants of vaccine supply.
    Natl Bur Econ Res Bull Aging Health; 2011; (3):2-3. PubMed ID: 22207917
    [No Abstract]   [Full Text] [Related]  

  • 6. The fragility of the U.S. vaccine supply.
    Sloan FA; Berman S; Rosenbaum S; Chalk RA; Giffin RB
    N Engl J Med; 2004 Dec; 351(23):2443-7. PubMed ID: 15575064
    [No Abstract]   [Full Text] [Related]  

  • 7. Overcoming economic barriers to the optimal use of vaccines.
    Lieu TA; McGuire TG; Hinman AR
    Health Aff (Millwood); 2005; 24(3):666-79. PubMed ID: 15886158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine manufacturing: challenges and solutions.
    Ulmer JB; Valley U; Rappuoli R
    Nat Biotechnol; 2006 Nov; 24(11):1377-83. PubMed ID: 17093488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Introducing new vaccines into developing countries: obstacles, opportunities and complexities.
    Clemens J; Jodar L
    Nat Med; 2005 Apr; 11(4 Suppl):S12-5. PubMed ID: 15812482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The winning shot. New vaccine technologies to offer pinpoint attacks on a variety of potentially deadly diseases.
    Kirchheimer B
    Mod Healthc; 2005 Nov; 35(46):52-4. PubMed ID: 16334833
    [No Abstract]   [Full Text] [Related]  

  • 11. Cash crisis looms for vaccine drive.
    Butler D
    Nature; 2010 Mar; 464(7287):338. PubMed ID: 20237535
    [No Abstract]   [Full Text] [Related]  

  • 12. Cautious industry welcome for US flu vaccine plan.
    Kling J
    Nat Biotechnol; 2005 Dec; 23(12):1457-8. PubMed ID: 16333275
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug and vaccine development for infectious diseases: the value of priority review vouchers.
    Matheny J; Smith B; Courtney B; Mair M
    Clin Pharmacol Ther; 2009 Jun; 85(6):571-2. PubMed ID: 19451907
    [No Abstract]   [Full Text] [Related]  

  • 14. Pandemic influenza vaccine: the US government is not doing enough.
    Osterholm MT
    Clin Pharmacol Ther; 2007 Dec; 82(6):635-7. PubMed ID: 17998909
    [No Abstract]   [Full Text] [Related]  

  • 15. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.
    Kesselheim AS
    Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908
    [No Abstract]   [Full Text] [Related]  

  • 16. Drugs and vaccines around the world.
    Health Aff (Millwood); 2006; 25(2):312. PubMed ID: 16522572
    [No Abstract]   [Full Text] [Related]  

  • 17. Strengthening the supply of routinely recommended vaccines in the United States: a perspective from the American Medical Association.
    Tan L;
    Clin Infect Dis; 2006 Mar; 42 Suppl 3():S121-4. PubMed ID: 16447133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine venture boosts health hopes.
    Butler D
    Nature; 2009 Sep; 461(7262):323. PubMed ID: 19759588
    [No Abstract]   [Full Text] [Related]  

  • 19. Federal government prepares for avian flu epidemic.
    Duvall D
    Consult Pharm; 2006 Apr; 21(4):345-6. PubMed ID: 16676450
    [No Abstract]   [Full Text] [Related]  

  • 20. National strategy for pandemic influenza released; $3.8 billion appropriated for pandemic preparedness.
    Mair M
    Biosecur Bioterror; 2006; 4(1):2-5. PubMed ID: 16602140
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.